*The following content is generated by AI and is for reference only.
Dorzolamide intermediate refers to a crucial precursor used in the synthesis of Dorzolamide hydrochloride, a well-known carbonic anhydrase inhibitor primarily employed as a topical ophthalmic solution for treating elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. While specific intermediates vary depending on the synthetic route adopted by pharmaceutical manufacturers, the most common structural core involves substituted 2-amino-4-methyl-5-thiophenesulfonamides or their cyclic derivatives, such as 2-amino-4-methyl-5-sulfamoylthiophene-3-carboxylic acid esters. The exact molecular formula and CAS number depend on the specific stage of synthesis; however, a representative key intermediate often cited is 2-amino-4-methyl-5-sulfamoylthiophene, which typically carries a CAS number around 107869-53-6 or similar variations based on substitution patterns, with a molecular formula generally approximating C5H8N2O2S2. These compounds serve as essential building blocks that undergo further chemical transformations, including cyclization and esterification, to form the final bicyclic structure of Dorzolamide.
The primary utility of these intermediates lies in their role within the pharmaceutical supply chain, ensuring the efficient and cost-effective production of high-purity active pharmaceutical ingredients (APIs). Manufacturers utilize them to optimize reaction yields, minimize by-products, and adhere to strict Good Manufacturing Practice (GMP) standards required for ophthalmic drugs. Given the sensitivity of eye treatments to impurities, the quality control of these intermediates is paramount to guarantee patient safety and therapeutic efficacy. Beyond standard glaucoma therapy, research continues into the potential applications of dorzolamide-related scaffolds for other conditions involving fluid regulation. As global demand for effective vision care solutions rises, the production and supply of these specialized chemical precursors remain a vital component of the broader medicinal chemistry landscape, supporting the development of next-generation ophthalmic formulations while maintaining rigorous regulatory compliance across international markets.